Antifungal Drugs: Technologies and Global Markets

The global market for antifungal drugs should grow from $14.6 billion in 2019 to reach $17.6 billion by 2024, at a compound annual growth rate (CAGR) of 3.8% for the forecast period of 2019-2024.

Report Includes

• 116 data tables and 27 additional tables
• An overview of the global markets for antifungal drugs within the pharmaceuticals industry
• Analyses of the global market trends, with data corresponding to market size from 2018 and 2019, and projections of compound annual growth rates (CAGRs) through 2024
• Comparative study of the two primary segments of antifungal medications – over-the-counter (OTC) and prescription based – and issues facing the use of these products
• Briefing about therapeutics in early development such as new molecular and biological entities from traditional pharmaceutical sources, naturally derived synthetic chemicals, and biological sources
• Review of antifungal agents and their classification based on the mechanism of action, approved therapeutic products and relevant patents with their expiration dates
• Information pertaining to R&D efforts, breakthrough therapy innovations, clinical trials of novel drug developments, their technologies and intended clinical applications
• Market share analysis of leading suppliers of antifungal drugs with related information about specific products, and their key competitive landscape
• Descriptive company profiles of major market players, including Astellas Pharma Inc., Bayer AG, Dr. Reddy's Laboratories Ltd., Gilead Sciences Inc., Janssen Pharmaceuticals Inc. (Johnson & Johnson), Pfizer Inc., Sanofi S.A., and Merck & Co., Inc.

The global market for antifungal drugs was valued at $13.1 billion in 2016. The market should reach $16.1 billion by 2021, growing at a compound annual growth rate (CAGR) of 4.2% from 2016 to 2021.

Report Includes

• An overview of the global market for antifungal drugs.
• Analyses of global market trends, with data from 2015, estimates for 2016, and projections of compound annual growth rates (CAGRs) through 2021.
• Identification of new antifungal research, development, and drug applications.
• Heavy focus on therapeutics in early development such as new molecular and biological entities from traditional pharmaceutical sources, naturally derived synthetic chemicals, and biological sources.
• Information on over the counter (OTC) vs. prescription products.
• Profiles of major players in the industry.

The global market for human antifungal therapeutics reached nearly $11.6 billion in 2012 and $11.8 billion in 2013. This market is expected to grow to nearly $13.9 billion in 2018 with a compound annual growth rate (CAGR) of 3.2% over the five-year period from 2013 to 2018.

Report Includes

• An overview of the global market for human antifungal therapeutics
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
• Identification of new antifungal research, development, and drug applications
• Information on over the counter (OTC) vs. prescription products
• Comprehensive profiles of leading companies in the industry.

The global market for antifungal therapeutics was valued at $10.7 billion in 2011 and is projected to reach $12.2 billion in 2016, a five-year compound annual growth rate (CAGR) of 2.7%.

• The global market for human antifungal therapeutics was valued at $9.8 billion in 2009 and is expected to increase at a compound annual growth rate (CAGR) of approximately 3.8% to reach $11.3 billion in 2014.
  
• The Latin and South American region will experience the greatest compound annual growth rate (CAGR) of 8.3%, reflecting an increase in revenues from $637 million in 2009 to $949 million in 2014.
  
• In North America, human antifungal therapeutics were valued at $3.9 billion in 2009 and are expected to increase at a 0.7% compound annual growth rate (CAGR) to reach $4 billion in 2014.

• The total global market for antifungal agents was worth more than $13.5 billion in 2005 and declined to just under $12.2 billion in 2006. The market will continue to dip through 2007 to $11.9 billion but will recover to more than $14.7 billion, a compound annual growth rate (CAGR) of 2.8%
• Antifungal agents for humans held the highest share of the market through the forecast period. In 2007 they will be worth more than $11.2 billion and will reach nearly $14 billion by 2012, a CAGR of 4.5%.
• Trends for fungal infections among animals are still a major concern as industry trends indicate. The market for animal antifungals will be worth $107 million in 2007 and will reach $110.7 million by 2012, a CAGR of 3.5%.

• The market for antifungal drugs is estimated at $5.9 billion in 2002, including both prescription and OTC products.
• Overall, the market is projected to rise at an average annual growth rate (AAGR) of 7.9% through 2007 to $8.7 billion.
• There are about 30 branded prescription systemic and topical antifungal agents on the market and several dozen over-the-counter branded and generic topical antifungal products.
• Products from several entirely new categories of compounds will be introduced during the forecast period.
• More than a dozen new prescription products are in clinical development and will contribute to the growth in this market.